stockrowAcumen Pharmaceuticals, Inc.
ABOS- EPS
- +20.3%
- Free cash flow
- +12.6%
- Total debt
- −14.3%
Quarter to September 2026, against a year earlier
Follow ABOS
Alert me
Acumen Pharmaceuticals, Inc. (ABOS) EV/Sales
As of 6 November 2026, Acumen Pharmaceuticals, Inc. (ABOS) trades at a EV/Sales of −25.4×. Over the past ten years it has ranged from −79.8× (March 2022) to 269× (October 2021); the current reading is higher than 34% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | −41.9× | — |
| FY2019 | −41.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | −41.9× | — |
| Sep 2020 | −41.9× | — |
| Jun 2020 | −41.9× | — |
| Mar 2020 | −41.9× | — |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VAXX Vaxxinity, Inc. compare | −94.2× |
| ABOS Acumen Pharmaceuticals, Inc. | −25.4× |
| NEUP Neuphoria Therapeutics Inc. compare | −0.4× |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | 1.7× |
| PLUR Pluri Inc. compare | 32.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)